ARCHIVES

Xeloda-Eloxatin Study Updated; Phase III Trial Interim Analysis

This article is from The Cancer Letter archive.

Vol. 25 No. 12 | December 27, 2002

Download PDF Visit The Full Archive

Related Articles

Sloan-Kettering Cited For 8 Violations Of NY State Standards

November 24, 1995

FDA Urges Lower Target for ESA Use; Market Could Drop By More Than Half.

March 16, 2007

Core Grant Guideline Revisions, Comprehensive Center Characteristics Changes Still Coming Up

July 13, 1979

Oklahoma’s new cigarette tax will provide $7 million a year to the University of Oklahoma Cancer Center.

November 5, 2004

Women’s Health Trial RFPs Issued; Three Clinical Centers Sought

April 12, 1991

Research Funding: 30 Groups Sign Letter For Double NCI Budget

January 23, 1998